Gilead Sciences' HIV Drug Eyed for Local Production by South Africa
MT Newswires Live
Mar 06
Gilead Sciences (GILD) is working with the South African government to come to an agreement that would enable the local production of HIV prevention drug lenacapavir, World Health Organization partner Unitaid said Friday.
The government is working with global health organizations, including Unitaid and United States Pharmacopeia, to identify a South African pharmaceutical manufacturer that can produce the drug with quality assurance, Unitaid said.
A finalized agreement would allow the manufacturer to become the seventh firm licensed to produce lenacapavir for low- and middle-income countries, joining six other firms in Egypt, India, and Pakistan, Unitaid said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.